[Evaluation on construction and expression in vitro of nucleic acid vaccine of nucleoprotein of influenza virus A].
OBJECTIVE
Constructing nucleic acid vaccine of influenza virus A to study the protective effects.


METHODS
NP gene was reverse transcripted from influenza virus A and linked with pSECTAG 2/Hygro A to constructed nucleic acid vaccine of influenza virus A. The constructed nucleic acid vaccine was transinfected into VERO cell resorting to lipofectamineTM2000. NP gene of influenza virus A was expressed in VERO cell by the method of ELISA.


RESULTS
The results showed that the NP gene was expressed to the highest level at 36h after transinfection with the A40 value of 0.382. From 36 h to 60 h after transinfection, the expression of NP gene was stable (the A45, value at 48h and 60h was 0.385 and 0.387, respectively) .


CONCLUSIONS
The nucleic acid vaccine of influenza virus A was successfully constructed, which sets up groudworks for the research of effection of nucleic acid vaccine in vivo.
He
Jian-Fan
JF
Shenzhen Center for Disease Control and Prevention, Shenzhen 518020, China.
Fang
Shi-Song
SS
Cheng
Xiao-Wen
XW
Zhang
Ran
R
Deng
Pingjian
P
Zhao
Shujin
S
D000818:Animals; D001483:Base Sequence; D002522:Chlorocebus aethiops; D009980:Influenza A virus / Q000235:genetics / Q000276:immunology*; D007252:Influenza Vaccines / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D008969:Molecular Sequence Data; D019590:Nucleocapsid Proteins; D016133:Polymerase Chain Reaction / Q000379:methods; D016601:RNA-Binding Proteins / Q000235:genetics / Q000276:immunology*; D014162:Transfection; D019444:Vaccines, DNA / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D014709:Vero Cells; D014758:Viral Core Proteins / Q000235:genetics / Q000276:immunology*
D007252:Influenza Vaccines; C048842:NP protein, Influenza A virus; D019590:Nucleocapsid Proteins; D016601:RNA-Binding Proteins; D019444:Vaccines, DNA; D014758:Viral Core Proteins